Time course and clinical characterization of cisplatin‐induced ototoxicity after treatment for nasopharyngeal carcinoma in a South East Asian population

Background The purpose of this study was to characterize the clinical course of hearing loss in patients with nasopharyngeal carcinoma (NPC) and the clinical factors affecting its severity. Methods The time course of hearing loss in patients with NPC was assessed using threshold shift from baseline...

Full description

Saved in:
Bibliographic Details
Published in:Head & neck 2018-07, Vol.40 (7), p.1425-1433
Main Authors: Chan, Sze Ling, Ng, Li Shia, Goh, Xueying, Siow, Chor Hiang, Goh, Han Lee, Goh, Boon Cher, Cheo, Timothy, Loh, Kwok Seng, Brunham, Liam R.
Format: Article
Language:English
Subjects:
Asian
Chemoradiotherapy
Chemotherapy
Cisplatin
Cochlea
Head and neck
Hearing loss
Nasopharyngeal carcinoma
Ototoxicity
Patients
Radiation therapy
radiotherapy
Terminology
Throat cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The purpose of this study was to characterize the clinical course of hearing loss in patients with nasopharyngeal carcinoma (NPC) and the clinical factors affecting its severity. Methods The time course of hearing loss in patients with NPC was assessed using threshold shift from baseline and Common Terminology Criteria for Adverse Events (CTCAE) grade. Results In the chemoradiotherapy (CRT) groups, the threshold shift was significantly higher from 3 months at 4 kHz (P = 2.30 × 10−9, concurrent CRT only) but not within 2 years posttreatment in the radiotherapy (RT) group. The CRT groups had worse CTCAE grades than the RT group (percentage of latest CTCAE grade ≥1: 64.9% vs 29.0%, respectively). Cumulative cisplatin dose and cochlear RT dose significantly affects threshold shifts, especially at high frequencies. Conclusion Although cisplatin led to high frequency hearing impairment from about 3 months posttreatment, RT conferred no significant hearing impairment in the first 2 years.
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.25112